JP2017504642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504642A5 JP2017504642A5 JP2016549279A JP2016549279A JP2017504642A5 JP 2017504642 A5 JP2017504642 A5 JP 2017504642A5 JP 2016549279 A JP2016549279 A JP 2016549279A JP 2016549279 A JP2016549279 A JP 2016549279A JP 2017504642 A5 JP2017504642 A5 JP 2017504642A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- substituted
- cycloalkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 190
- 125000000623 heterocyclic group Chemical group 0.000 claims 122
- 229910052739 hydrogen Inorganic materials 0.000 claims 75
- 229910052799 carbon Inorganic materials 0.000 claims 53
- 229910052731 fluorine Inorganic materials 0.000 claims 51
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 48
- 229910052736 halogen Inorganic materials 0.000 claims 43
- 150000002367 halogens Chemical class 0.000 claims 43
- 125000003118 aryl group Chemical group 0.000 claims 37
- 229910052801 chlorine Inorganic materials 0.000 claims 33
- 125000004452 carbocyclyl group Chemical group 0.000 claims 31
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 30
- 229910052760 oxygen Inorganic materials 0.000 claims 26
- 229910052757 nitrogen Inorganic materials 0.000 claims 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 21
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims 19
- 125000001188 haloalkyl group Chemical group 0.000 claims 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 19
- 229910052794 bromium Inorganic materials 0.000 claims 17
- -1 —S (═O) 2 NH 2 Chemical group 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 230000009424 thromboembolic effect Effects 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000006809 haloalkylaminocarbonyl group Chemical group 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000005221 halo alkyl carbonyl amino group Chemical group 0.000 claims 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010014513 Embolism arterial Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010063544 Renal embolism Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000005242 cardiac chamber Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000002528 coronary thrombosis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000003836 peripheral circulation Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000005060 thrombophlebitis Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933942P | 2014-01-31 | 2014-01-31 | |
| US61/933,942 | 2014-01-31 | ||
| US201462058293P | 2014-10-01 | 2014-10-01 | |
| US62/058,293 | 2014-10-01 | ||
| PCT/US2015/013654 WO2015116886A1 (en) | 2014-01-31 | 2015-01-30 | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019060181A Division JP6854067B2 (ja) | 2014-01-31 | 2019-03-27 | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504642A JP2017504642A (ja) | 2017-02-09 |
| JP2017504642A5 true JP2017504642A5 (show.php) | 2018-06-07 |
| JP6505727B2 JP6505727B2 (ja) | 2019-04-24 |
Family
ID=52484570
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549279A Active JP6505727B2 (ja) | 2014-01-31 | 2015-01-30 | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2016549277A Active JP6464176B2 (ja) | 2014-01-31 | 2015-01-30 | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2019000516A Active JP6630004B2 (ja) | 2014-01-31 | 2019-01-07 | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2019060181A Active JP6854067B2 (ja) | 2014-01-31 | 2019-03-27 | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2021039989A Active JP7325464B2 (ja) | 2014-01-31 | 2021-03-12 | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2023125512A Pending JP2023133468A (ja) | 2014-01-31 | 2023-08-01 | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2025166031A Pending JP2025185049A (ja) | 2014-01-31 | 2025-10-02 | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549277A Active JP6464176B2 (ja) | 2014-01-31 | 2015-01-30 | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2019000516A Active JP6630004B2 (ja) | 2014-01-31 | 2019-01-07 | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2019060181A Active JP6854067B2 (ja) | 2014-01-31 | 2019-03-27 | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2021039989A Active JP7325464B2 (ja) | 2014-01-31 | 2021-03-12 | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2023125512A Pending JP2023133468A (ja) | 2014-01-31 | 2023-08-01 | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2025166031A Pending JP2025185049A (ja) | 2014-01-31 | 2025-10-02 | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20170002006A1 (show.php) |
| EP (4) | EP3099686B1 (show.php) |
| JP (7) | JP6505727B2 (show.php) |
| KR (3) | KR20240017118A (show.php) |
| CN (4) | CN105980384B (show.php) |
| AU (5) | AU2015210904C1 (show.php) |
| BR (1) | BR112016015717B1 (show.php) |
| CA (1) | CA2937739C (show.php) |
| CL (1) | CL2016001933A1 (show.php) |
| CY (1) | CY1120702T1 (show.php) |
| DK (1) | DK3099687T3 (show.php) |
| EA (1) | EA030222B1 (show.php) |
| ES (3) | ES2893251T3 (show.php) |
| HR (1) | HRP20181339T1 (show.php) |
| HU (1) | HUE040226T2 (show.php) |
| IL (5) | IL307212A (show.php) |
| LT (1) | LT3099687T (show.php) |
| MX (2) | MX377545B (show.php) |
| MY (1) | MY190429A (show.php) |
| NZ (2) | NZ723762A (show.php) |
| PE (2) | PE20161069A1 (show.php) |
| PH (2) | PH12016501249B1 (show.php) |
| PL (1) | PL3099687T3 (show.php) |
| PT (1) | PT3099687T (show.php) |
| RS (1) | RS57659B1 (show.php) |
| SG (2) | SG11201606209PA (show.php) |
| SI (1) | SI3099687T1 (show.php) |
| SM (1) | SMT201800505T1 (show.php) |
| TW (4) | TWI688564B (show.php) |
| UY (3) | UY35971A (show.php) |
| WO (2) | WO2015116886A1 (show.php) |
| ZA (1) | ZA201606011B (show.php) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| TWI586651B (zh) | 2011-10-14 | 2017-06-11 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物 |
| WO2014160668A1 (en) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| UY35971A (es) * | 2014-01-31 | 2015-07-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia |
| NO2760821T3 (show.php) | 2014-01-31 | 2018-03-10 | ||
| EP2913330A1 (en) * | 2014-02-27 | 2015-09-02 | Laboratoire Biodim | Condensed derivatives of imidazole useful as pharmaceuticals |
| US10081623B2 (en) | 2014-09-04 | 2018-09-25 | Bristol-Myers Squibb Company | Diamide macrocycles that are FXIa inhibitors |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (show.php) * | 2014-10-01 | 2018-10-20 | ||
| KR102457840B1 (ko) | 2014-10-01 | 2022-10-21 | 메르크 파텐트 게엠베하 | 보론산 유도체 |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CN108026083B (zh) | 2015-06-19 | 2021-08-27 | 百时美施贵宝公司 | 作为因子xia抑制剂的二酰胺大环 |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| KR102729666B1 (ko) | 2015-07-29 | 2024-11-12 | 브리스톨-마이어스 스큅 컴퍼니 | 비-방향족 P2' 기를 갖는 인자 XIa 신규 마크로사이클 |
| EP3328851B1 (en) * | 2015-07-29 | 2020-04-22 | Bristol-Myers Squibb Company | Factor xia macrocyclic inhibitors bearing alkyl or cycloalkyl p2' moieties |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| US10344039B2 (en) | 2015-10-29 | 2019-07-09 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use |
| CN108430471B (zh) * | 2015-10-29 | 2021-07-09 | 默沙东公司 | 因子XIa抑制剂 |
| JP2019507167A (ja) | 2016-03-02 | 2019-03-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害活性を有するジアミド大員環 |
| BR112018069601A2 (pt) | 2016-03-31 | 2019-01-29 | Janssen Pharmaceuticals Inc | derivados de indolina substituídos como inibidores da replicação viral da dengue |
| CR20180495A (es) | 2016-03-31 | 2018-12-06 | Univ Leuven Kath | Deribados de indol sustituidos como inhibidores de replicación viral del dengue |
| CN109069482B (zh) | 2016-04-01 | 2022-04-05 | 杨森制药公司 | 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物 |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| AR109304A1 (es) | 2016-08-10 | 2018-11-21 | Sumitomo Chemical Co | Compuesto de oxadiazol y su uso |
| WO2018039094A1 (en) | 2016-08-22 | 2018-03-01 | Merck Sharp & Dohme Corp. | Pyridine-1-oxide derivatives and their use as factor xia inhibitors |
| CN110062757B (zh) * | 2017-01-18 | 2022-03-04 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CN110691773B (zh) | 2017-05-22 | 2023-06-23 | 杨森制药公司 | 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物 |
| EP3630724B1 (en) | 2017-05-22 | 2021-04-28 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| WO2019011166A1 (zh) * | 2017-07-14 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 大环酰胺化合物及其药物组合物和用途 |
| MX2021012286A (es) | 2019-04-11 | 2022-04-06 | Bristol Myers Squibb Co | Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6 -oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-he xahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6 h)-ona. |
| PE20212367A1 (es) * | 2019-04-11 | 2021-12-21 | Bristol Myers Squibb Co | Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas |
| EP3957638B1 (en) * | 2019-04-16 | 2025-01-08 | China Resources Biopharmaceutical Company Limited | Macrocyclic derivatives acting as xia factor inhibitor |
| US20220281868A1 (en) | 2019-07-23 | 2022-09-08 | Medshine Discovery Inc. | Macrocyclic derivatives as factor xia inhibitors |
| TWI749881B (zh) * | 2019-11-21 | 2021-12-11 | 大陸商深圳信立泰藥業股份有限公司 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
| CA3179957A1 (en) * | 2020-04-10 | 2021-10-14 | Bristol-Myers Squibb Company | Crystalline forms of (9r,13s)-13-{4-[5-chloro-2-(4-chloro-1h,2,3-triazol- 1 -yl)phenyl]-6-oxo-1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricy clo[12.3.1.02·6]octadeca- 1(18),2(6),4,14,16-pentaen-8-one |
| TW202229280A (zh) * | 2020-10-12 | 2022-08-01 | 美商必治妥美雅史谷比公司 | （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法 |
| JP7517964B2 (ja) * | 2020-11-27 | 2024-07-17 | シャープ株式会社 | 電子機器、電子機器の制御方法、プログラム、記録媒体 |
| CN112608274B (zh) * | 2020-12-30 | 2022-09-06 | 西南大学 | 一种手性胺化合物的催化合成方法及其化合物 |
| PE20240689A1 (es) * | 2021-01-08 | 2024-04-10 | Bristol Myers Squibb Co | Anticuerpos y peptidos de union a antigenos para inhibidores del factor xia y uso de los mismos |
| CN112876461B (zh) * | 2021-01-20 | 2022-12-30 | 上海零诺生物科技有限公司 | 尼古丁及其中间体的制备方法 |
| WO2022222960A1 (zh) * | 2021-04-21 | 2022-10-27 | 上海美悦生物科技发展有限公司 | FXIa抑制剂及其药物组合物、制备方法和用途 |
| AR128430A1 (es) * | 2022-02-03 | 2024-05-08 | De Shaw Res Llc | Compuestos de piridazinona como inhibidores de trpa1 |
| CR20240533A (es) * | 2022-06-08 | 2025-03-10 | Blossomhill Therapeutics Inc | Macrociclos de indazol y su uso |
| CN119894901A (zh) * | 2023-06-30 | 2025-04-25 | 深圳信立泰药业股份有限公司 | 一种多取代的大环化合物及其制备方法与应用 |
| WO2025224678A1 (en) | 2024-04-25 | 2025-10-30 | Assia Chemical Industries Ltd. | Solid state forms of milvexian and process for preparation thereof |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1525186A (fr) | 1967-03-29 | 1968-05-17 | Roussel Uclaf | Nouvelles pénicillines et procédé de préparation |
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| DE4034829A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | Cyclopeptide |
| JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| US5624936A (en) | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1996034010A2 (en) | 1995-03-29 | 1996-10-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2249617A1 (en) | 1996-04-03 | 1997-10-09 | S. Jane Desolms | Inhibitors of farnesyl-protein transferase |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
| TR200103406T2 (tr) | 1998-03-19 | 2002-06-21 | Vertex Pharmaceuticals Incorporated | Kaspaz inhibitörleri. |
| ES2310039T3 (es) | 1998-05-26 | 2008-12-16 | Warner-Lambert Company Llc | Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular. |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| EP1016663A1 (en) | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) |
| HUP0105437A3 (en) | 1999-01-02 | 2003-03-28 | Aventis Pharma Gmbh | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
| BR0009678A (pt) | 1999-04-09 | 2002-01-22 | Basf Ag | Compostos, composição farmacêutica, e, uso de compostos |
| AU5546000A (en) | 1999-06-14 | 2001-01-02 | Protherics Molecular Design Limited | Compounds |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| BR0110638A (pt) | 2000-05-11 | 2003-03-25 | Bristol Myers Squibb Co | Análogos de tetraidroisoquinolina úteis como secretagogos de hormÈnio do crescimento |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| AU2002322802A1 (en) | 2001-07-27 | 2003-02-17 | Merck And Co., Inc. | Thrombin inhibitors |
| US6951840B2 (en) | 2001-08-31 | 2005-10-04 | Eli Lilly And Company | Lipoglycopeptide antibiotics |
| HRP20040280B1 (hr) | 2001-09-21 | 2013-09-30 | Bristol-Myers Squibb Company A Delaware (Usa) Corporation | SPOJEVI KOJI SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa |
| WO2003041641A2 (en) | 2001-11-09 | 2003-05-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| AU2002316317A1 (en) | 2002-06-18 | 2003-12-31 | The Scripps Research Institute | Synthesis of diazonamide "a" core |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US20100190688A1 (en) | 2004-07-12 | 2010-07-29 | Bin Chao | Tetrapeptide analogs |
| JP5236293B2 (ja) | 2005-01-13 | 2013-07-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｘｉａ因子阻害剤としての置換ビアリール化合物 |
| US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
| US20070111947A1 (en) | 2005-10-14 | 2007-05-17 | Mcmurry Thomas J | Fibrin targeted therapeutics |
| AU2006311101A1 (en) | 2005-11-11 | 2007-05-18 | F. Hoffmann-La Roche Ag | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor Xa |
| AU2006325746A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2007070826A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
| AR058380A1 (es) | 2005-12-23 | 2008-01-30 | Bristol Myers Squibb Co | Inhibidores del factor viia macrociclicos utiles como anticoagulantes |
| CN101389613B (zh) * | 2005-12-23 | 2011-10-12 | 布里斯托尔-迈尔斯.斯奎布公司 | 用作抗凝血药的大环凝血因子viia抑制剂 |
| CN101605779B (zh) | 2006-12-15 | 2013-11-20 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物 |
| PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| US8367709B2 (en) | 2007-06-13 | 2013-02-05 | Bristol-Myers Squibb Company | Dipeptide analogs as coagulation factor inhibitors |
| EP2265601B1 (en) | 2008-03-13 | 2012-02-01 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| US8624040B2 (en) | 2009-06-22 | 2014-01-07 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US8513433B2 (en) | 2009-07-02 | 2013-08-20 | Angion Biomedica Corp. | Small molecule inhibitors of PARP activity |
| AR077695A1 (es) | 2009-08-04 | 2011-09-14 | Schering Corp | Derivados de pirimidina como inhibidores del factor ixa |
| JP2013504575A (ja) * | 2009-09-09 | 2013-02-07 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 除草性ピリミドン誘導体 |
| CN102834397B (zh) * | 2010-02-11 | 2016-02-03 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的大环化合物 |
| US9161924B2 (en) | 2011-07-08 | 2015-10-20 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) * | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TWI586651B (zh) | 2011-10-14 | 2017-06-11 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物 |
| WO2013055984A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| IN2014CN02805A (show.php) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| GB2497806A (en) | 2011-12-21 | 2013-06-26 | Ono Pharmaceutical Co | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| ES2765891T3 (es) * | 2011-12-21 | 2020-06-11 | Ono Pharmaceutical Co | Derivados de piridinona y pirimidinona como inhibidores del factor XIa |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| SG10201609322QA (en) | 2012-05-10 | 2017-01-27 | Bayer Pharma AG | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| GB201209138D0 (en) | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
| WO2014014050A1 (ja) | 2012-07-19 | 2014-01-23 | 大日本住友製薬株式会社 | １－（シクロアルキルカルボニル）プロリン誘導体 |
| PT2880026T (pt) | 2012-08-03 | 2017-05-03 | Bristol Myers Squibb Co | Dihidropiridona p1 como inibidores de fator xia |
| ES2605824T3 (es) | 2012-08-03 | 2017-03-16 | Bristol-Myers Squibb Company | Dihidropiridona como inhibidores del factor XIa |
| WO2014059214A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| NZ707990A (en) | 2012-10-12 | 2018-07-27 | Bristol Myers Squibb Co | Crystalline forms of a factor xia inhibitor |
| EP2934538B1 (en) | 2012-12-19 | 2021-03-31 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| WO2014160668A1 (en) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| CA2918814C (en) | 2013-07-23 | 2021-10-12 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| US20160244437A1 (en) | 2013-09-26 | 2016-08-25 | Bayer Pharma Aktiengesellschaft | Substituted phenylalanine derivatives |
| US20160237044A1 (en) | 2013-09-26 | 2016-08-18 | Bayer Pharma Aktiengesellschaft | Substituted phenylalanine derivatives |
| CA2925291A1 (en) | 2013-09-26 | 2015-04-02 | Bayer Pharma Aktiengesellschaft | Substituted phenylalanine derivatives |
| WO2015044169A1 (de) | 2013-09-26 | 2015-04-02 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate |
| WO2015044174A1 (de) | 2013-09-26 | 2015-04-02 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate als faktor xia modulatoren |
| US20160237045A1 (en) | 2013-09-26 | 2016-08-18 | Bayer Pharma Aktiengesellschaft | Substituted phenylalanine derivatives |
| US20160280699A1 (en) | 2013-09-26 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Substituted phenylalanine derivatives |
| TW201605828A (zh) | 2013-09-26 | 2016-02-16 | 拜耳製藥股份有限公司 | 經取代苯丙胺酸衍生物（三） |
| EP3049435A4 (en) | 2013-09-27 | 2017-03-29 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| EP3054944B1 (en) | 2013-10-07 | 2019-12-04 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| JP6337750B2 (ja) | 2013-11-22 | 2018-06-06 | 小野薬品工業株式会社 | 化合物 |
| CN106103453A (zh) | 2014-01-14 | 2016-11-09 | 大日本住友制药株式会社 | 缩合5‑噁唑烷酮衍生物 |
| UY35971A (es) | 2014-01-31 | 2015-07-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia |
| NO2760821T3 (show.php) | 2014-01-31 | 2018-03-10 | ||
| RU2733405C2 (ru) | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| EP3104703B1 (en) | 2014-02-11 | 2020-11-18 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| US9663527B2 (en) | 2014-02-11 | 2017-05-30 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| US9676723B2 (en) | 2014-02-11 | 2017-06-13 | Merck Sharp & Dohme Corp | Factor XIa inhibitors |
| EP3138839B1 (en) | 2014-02-14 | 2020-10-28 | Sichuan Haisco Pharmaceutical Co., Ltd. | Pyridone or pyrimidone derivative, preparation method therefor and application thereof |
| HUE052668T2 (hu) | 2014-03-07 | 2021-05-28 | Biocryst Pharm Inc | Trifluorometillel szubsztituált pirazolok mint humán plazma kallikrein-gátlók |
| EP3131897B8 (en) | 2014-04-16 | 2022-08-03 | Merck Sharp & Dohme LLC | Factor ixa inhibitors |
| US9808445B2 (en) | 2014-04-16 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| GB201409202D0 (en) * | 2014-05-23 | 2014-07-09 | Ffei Ltd | Improvements in imaging microscope samples |
| KR20150136294A (ko) | 2014-05-27 | 2015-12-07 | 주식회사 레고켐 바이오사이언스 | 인자 ＸＩａ 억제 활성을 가지는 신규한 화합물 |
| MX2016015484A (es) | 2014-05-28 | 2017-03-23 | Merck Sharp & Dohme | Inhibidores del factor xia. |
| EP3197891B1 (de) | 2014-09-24 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate |
| US9453018B2 (en) * | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (show.php) * | 2014-10-01 | 2018-10-20 | ||
| PT3231803T (pt) | 2014-12-10 | 2020-09-03 | Ono Pharmaceutical Co | Derivado de di-hidroindolizinona |
| CN108026083B (zh) | 2015-06-19 | 2021-08-27 | 百时美施贵宝公司 | 作为因子xia抑制剂的二酰胺大环 |
-
2015
- 2015-01-30 UY UY0001035971A patent/UY35971A/es not_active Application Discontinuation
- 2015-01-30 KR KR1020247003206A patent/KR20240017118A/ko not_active Ceased
- 2015-01-30 LT LTEP15705860.3T patent/LT3099687T/lt unknown
- 2015-01-30 CN CN201580006495.1A patent/CN105980384B/zh active Active
- 2015-01-30 EP EP15705428.9A patent/EP3099686B1/en active Active
- 2015-01-30 CN CN201580017440.0A patent/CN106132962B/zh active Active
- 2015-01-30 BR BR112016015717-6A patent/BR112016015717B1/pt active IP Right Grant
- 2015-01-30 SM SM20180505T patent/SMT201800505T1/it unknown
- 2015-01-30 JP JP2016549279A patent/JP6505727B2/ja active Active
- 2015-01-30 SG SG11201606209PA patent/SG11201606209PA/en unknown
- 2015-01-30 MY MYPI2016702666A patent/MY190429A/en unknown
- 2015-01-30 TW TW104103366A patent/TWI688564B/zh active
- 2015-01-30 HR HRP20181339TT patent/HRP20181339T1/hr unknown
- 2015-01-30 ES ES18174593T patent/ES2893251T3/es active Active
- 2015-01-30 JP JP2016549277A patent/JP6464176B2/ja active Active
- 2015-01-30 IL IL307212A patent/IL307212A/en unknown
- 2015-01-30 CN CN201911001057.2A patent/CN110845498B/zh active Active
- 2015-01-30 DK DK15705860.3T patent/DK3099687T3/en active
- 2015-01-30 ES ES15705860.3T patent/ES2687498T3/es active Active
- 2015-01-30 TW TW111149560A patent/TWI859674B/zh active
- 2015-01-30 WO PCT/US2015/013654 patent/WO2015116886A1/en not_active Ceased
- 2015-01-30 CA CA2937739A patent/CA2937739C/en active Active
- 2015-01-30 IL IL322255A patent/IL322255A/en unknown
- 2015-01-30 NZ NZ723762A patent/NZ723762A/en unknown
- 2015-01-30 WO PCT/US2015/013652 patent/WO2015116885A1/en not_active Ceased
- 2015-01-30 MX MX2016009230A patent/MX377545B/es active IP Right Grant
- 2015-01-30 HU HUE15705860A patent/HUE040226T2/hu unknown
- 2015-01-30 CN CN202310156065.4A patent/CN116987080A/zh active Pending
- 2015-01-30 UY UY0001035975A patent/UY35975A/es active IP Right Grant
- 2015-01-30 EA EA201691471A patent/EA030222B1/ru not_active IP Right Cessation
- 2015-01-30 KR KR1020227021266A patent/KR102631769B1/ko active Active
- 2015-01-30 RS RS20181028A patent/RS57659B1/sr unknown
- 2015-01-30 UY UY0001040230A patent/UY40230A/es not_active Application Discontinuation
- 2015-01-30 SG SG10201908467R patent/SG10201908467RA/en unknown
- 2015-01-30 IL IL298983A patent/IL298983B2/en unknown
- 2015-01-30 TW TW104103305A patent/TW201613922A/zh unknown
- 2015-01-30 PE PE2016001274A patent/PE20161069A1/es unknown
- 2015-01-30 SI SI201530317T patent/SI3099687T1/en unknown
- 2015-01-30 TW TW109105925A patent/TWI790421B/zh active
- 2015-01-30 EP EP18174593.6A patent/EP3392249B1/en active Active
- 2015-01-30 EP EP21192647.2A patent/EP3988549A1/en active Pending
- 2015-01-30 US US15/115,327 patent/US20170002006A1/en not_active Abandoned
- 2015-01-30 PT PT15705860T patent/PT3099687T/pt unknown
- 2015-01-30 KR KR1020167023481A patent/KR102413453B1/ko active Active
- 2015-01-30 AU AU2015210904A patent/AU2015210904C1/en active Active
- 2015-01-30 EP EP15705860.3A patent/EP3099687B1/en active Active
- 2015-01-30 PL PL15705860T patent/PL3099687T3/pl unknown
- 2015-01-30 PE PE2020002136A patent/PE20210470A1/es unknown
- 2015-01-30 US US15/115,314 patent/US9777001B2/en active Active
- 2015-01-30 NZ NZ761182A patent/NZ761182A/en unknown
- 2015-01-30 ES ES15705428T patent/ES2784841T3/es active Active
-
2016
- 2016-06-24 PH PH12016501249A patent/PH12016501249B1/en unknown
- 2016-07-14 MX MX2020012520A patent/MX2020012520A/es unknown
- 2016-07-26 IL IL246964A patent/IL246964B/en active IP Right Grant
- 2016-07-29 CL CL2016001933A patent/CL2016001933A1/es unknown
- 2016-08-30 ZA ZA2016/06011A patent/ZA201606011B/en unknown
-
2018
- 2018-09-28 CY CY181101000T patent/CY1120702T1/el unknown
-
2019
- 2019-01-07 JP JP2019000516A patent/JP6630004B2/ja active Active
- 2019-03-27 JP JP2019060181A patent/JP6854067B2/ja active Active
- 2019-08-13 AU AU2019216617A patent/AU2019216617B2/en active Active
-
2020
- 2020-01-30 IL IL272377A patent/IL272377B2/en unknown
-
2021
- 2021-02-26 PH PH12021550418A patent/PH12021550418A1/en unknown
- 2021-03-12 JP JP2021039989A patent/JP7325464B2/ja active Active
- 2021-06-15 AU AU2021203968A patent/AU2021203968B2/en active Active
-
2023
- 2023-06-14 AU AU2023203695A patent/AU2023203695A1/en not_active Abandoned
- 2023-08-01 JP JP2023125512A patent/JP2023133468A/ja active Pending
-
2025
- 2025-03-17 AU AU2025201886A patent/AU2025201886A1/en active Pending
- 2025-10-02 JP JP2025166031A patent/JP2025185049A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504642A5 (show.php) | ||
| JP2017504641A5 (show.php) | ||
| JP2021088610A5 (show.php) | ||
| JP2014521700A5 (show.php) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2019094345A5 (show.php) | ||
| JP2018517753A5 (show.php) | ||
| JP2013500314A5 (show.php) | ||
| JP2020526565A5 (show.php) | ||
| JP2015524443A5 (show.php) | ||
| JP2019518766A5 (show.php) | ||
| IL298983B2 (en) | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors | |
| JP2018510139A5 (show.php) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2020502047A5 (show.php) | ||
| JP2014532070A5 (show.php) | ||
| JP2014530240A5 (show.php) | ||
| JP2019509978A5 (show.php) | ||
| JP2015532295A5 (show.php) | ||
| JP2016531126A5 (show.php) | ||
| JP2016534148A5 (show.php) | ||
| JP2017525744A5 (show.php) | ||
| JP2020521767A5 (show.php) | ||
| JP2020532547A5 (show.php) | ||
| JP2020532545A5 (show.php) |